Cross-Border Impact Ventures

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

Our strategy leverages an extensive hospital system and health plan network of relationships to target attractive market segments, to identify and evaluate investment opportunities, and to support the growth of our portfolio companies. Current Areas of Focus:Administrative Automation Behavioral Health: HCIT & Services Data Security Digital Therapeutics Genomics: Applications & Analytics Patient Safety & Risk Monitoring Pharma Data & Analytics Platforms Social Determinants of Health Virtual Care Models Women’s Health: HCIT & Services

As part of our investment approach, we developed a structured evaluation process, the “FemHealth Framework.” The first element (re)imagines women’s health as conditions appearing only in women, mostly in women, and differently in women. This concept from the FemHealth Framework (© 2019 FemHealth Ventures) was first published in 2019 and is increasingly thought of as a new lens through which to view women’s health. At FemHealth Ventures, we are excited about the increasing adoption of this broader definition of women’s health and the exciting new treatments it will engender. Only in Women Some conditions appear only in women. Examples include: endometriosis polycystic ovarian syndrome cervical cancer Mostly in Women Some conditions appear mostly in women. Examples include: breast cancer lupus multiple sclerosis Differently in Women Some conditions appear differently in women. Examples include: heart disease diabetes asthma Every cell has a sex A universe of possibilities is opened in women’s health when we start with the most basic building block: our cells. Each of the 30 trillion cells in a woman’s body has a different chromosomal makeup than a man. For example, a skin cell from a woman will have XX chromosomes, but a skin cell from a man will have XY chromosomes. This difference between women and men holds true throughout every single cell in the body. As a result, even the same disease can present differently in women versus men and require distinct treatment paradigms. Women’s health is more than “bikini medicine.” The term “bikini medicine” generally refers to conditions treated by obstetricians or gynecologists. We’ve (re)imagined women’s health as a broad spectrum of conditions that can impact the whole body, ranging from ovarian cancer, to autoimmune disease, to cardiovascular disease, and everything in between. A multitude of possibilities for innovation in women’s health exist. And we are here to help bring them to life.

We see enormous opportunity in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns for our investors. Adjuvant’s investment model is heavily influenced by global trends such as climate change, the empowerment of women and girls, urbanization, antimicrobial resistance, and globalization. These trends guide us toward looming public health threats and the high impact innovations that will address them. Built to Improve Health, for Everyone Our mission is simple: invest in the most promising public health technologies and ensure they are made accessible to those who need them most. We invest in innovative technologies to address high-burden and neglected infectious diseases, maternal and child health, and reproductive and sexual health. Within the infectious disease category, we focus on the "big three" (HIV/AIDS, tuberculosis, malaria), tropical diseases like schistosomiasis and onchocerciasis, pandemic threats such as Middle East Respiratory Syndrome (MERS) and Lassa fever, and anti-microbial resistance (AMR). The majority of our investment activity is built upon commercializing technologies that have demonstrated safety and efficacy in humans, with the goal of accelerating the global availability of the most impactful medical innovations. Investing in a Changing World Healthcare spending in emerging economies is one of the fastest growing sectors in the world. Global economic growth is moving billions of people into the middle class, while the call for universal health equity is driving more resources than ever to healthcare for low-income populations. Despite these trends, life sciences investment in this large and growing segment is remarkably low. Our unique focus targets innovations poised to deliver unprecedented health outcomes in underserved markets with the goal of generating truly differentiated "double-bottom-line" returns for our investors. A Global Network of Investors Working to Build a Healthier Future Adjuvant is backed by leading strategic investors and alternative asset managers who understand the global public health landscape, providing invaluable domain expertise and support on top of their capital commitments.

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies. We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision. We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation. Investment Strategy Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital. Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit. Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity. Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.

Canada’s leading digital healthcare Venture Capital firm, offering local depth with global reach. We are healthcare practitioners, operators and founders with over 100 years’ experience and a deep network. We focus on early stage and high-growth companies shaping the future of healthcare delivery and empowering them to scale and grow. How We InvestStage: Investments will be in early stage companies ranging from pre-Seed rounds through pre-IPO with initial investments focused on Seed and Series A rounds Areas: We look for groundbreaking HealthTech ideas focusing on digitization of healthcare, emergence of consumer MedTech, and consumerization of health and wellness Locations: We invest primarily in companies located in Canada, the US and Israel that target markets in North America and Europe